Payer Perspectives on Biosimilars

Findings uncovered in "Payer Perspectives on Biosimilars" show:

• Oncology is the #1 therapeutic area where payers expect biosimilars to produce cost savings

• 54% of oncologists surveyed at a market research meeting reported that they were “not at all aware” about FDA regulation and pending legislation surrounding biosimilars
  
  
• 88% of oncologists surveyed at a separate meeting said that they were “not at all familiar” with recent legislation on comparative effectiveness

This report presents insights from payers combined with strategic analysis to help you understand the impact of biosimilars on biologic product access and reimbursement. Access more than 100 pages of valuable, credible, and actionable research that will help you develop the most effective strategies to optimize reimbursement for biologic therapies and understand the impact on branded biologics. Specific data includes:

• How health plans expect to evaluate biosimilar efficacy
  
• Managed care decision makers’ greatest concerns about biosimilars
  
• The discount managed care organizations expect from biosimilars in competitive categories
  
• How confident medical and pharmacy directors are in their plans’ abilities to challenge provider prescribing preferences and enforce biosimilar generic substitution requirements
  
• The therapeutic areas where managed care expects to realize the greatest cost savings after the introduction of biosimilar agent
  
• The manufacturers that managed care representatives believe are most likely to develop and market biosimilars
  
• How international production of biosimilar agents is expected to impact product uptake and coverage in the United States
  
• Implications for manufacturers

Turn to Xcenda for immediate access to market data that can improve your product’s success.